{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:45:35Z","timestamp":1792079135331,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05078-9","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:25:04Z","timestamp":1784532304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Meta-analysis: safety and efficacy of ustekinumab in pediatric inflammatory bowel disease patients with anti-TNF failure"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhaoyang","family":"Heng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Shoykot","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Most. Fatema","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"5078_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/diagnostics15111303","volume":"15","author":"AM Kaz","year":"2025","unstructured":"Kaz AM, Venu N. Diagnostic methods and biomarkers in inflammatory bowel disease. Diagnostics. 2025;15:1303. https:\/\/doi.org\/10.3390\/diagnostics15111303.","journal-title":"Diagnostics"},{"key":"5078_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, et al. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6:22. https:\/\/doi.org\/10.1038\/s41572-020-0156-2.","journal-title":"Nat Rev Dis Primers"},{"issue":"25","key":"5078_CR3","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.3748\/wjg.v24.i25.2741","volume":"24","author":"J S\u00fdkora","year":"2018","unstructured":"S\u00fdkora J, et al. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018;24(25):2741\u201363. https:\/\/doi.org\/10.3748\/wjg.v24.i25.2741.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"5078_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","volume":"162","author":"ME Kuenzig","year":"2022","unstructured":"Kuenzig ME, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease. Syst Rev Gastroenterol. 2022;162(4):1147\u2013e11594. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.282.","journal-title":"Syst Rev Gastroenterol"},{"key":"5078_CR5","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.3390\/nu17223545","volume":"17","author":"ME Capra","year":"2025","unstructured":"Capra ME, Bellani AM, Berzieri M, et al. Nutritional approach in pediatric patients with inflammatory bowel disease: Treatment, risk and challenges. Nutrients. 2025;17:3545. https:\/\/doi.org\/10.3390\/nu17223545.","journal-title":"Nutrients"},{"key":"5078_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.33590\/emjinnov\/21-00134","volume":"6","author":"KA Falloon","year":"2022","unstructured":"Falloon KA, Fiocchi C. Current therapy in inflammatory bowel disease: why and how we need to change? EMJ Innovations. 2022;6:21\u201300134. https:\/\/doi.org\/10.33590\/emjinnov\/21-00134.","journal-title":"EMJ Innovations"},{"key":"5078_CR7","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1053\/j.gastro.2025.01.069","volume":"168","author":"S Rabeeah","year":"2025","unstructured":"Rabeeah S, et al. Comparative efficacy of vedolizumab versus ustekinumab in ulcerative colitis patients after anti-TNF therapy failure. Gastroenterology. 2025;168:S11\u20132. https:\/\/doi.org\/10.1053\/j.gastro.2025.01.069.","journal-title":"Gastroenterology"},{"issue":"13","key":"5078_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"key":"5078_CR9","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1602773.","journal-title":"N Engl J Med"},{"key":"5078_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/jpn3.12452","volume":"80","author":"EB Mitchel","year":"2025","unstructured":"Mitchel EB, et al. Ustekinumab is safe and effective in pediatric patients with Crohn\u2019s disease. J Pediatr Gastroenterol Nutr. 2025;80:653\u201363. https:\/\/doi.org\/10.1002\/jpn3.12452.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5078_CR11","unstructured":"PROSPERO International prospective register of systematic reviews. University of York, York (UK). 2011. https:\/\/www.crd.york.ac.uk\/prospero\/. Accessed 13 Jan 2026."},{"key":"5078_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"5078_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, et al. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"key":"5078_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"5078_CR15","doi-asserted-by":"publisher","first-page":"Ed000142","DOI":"10.1002\/14651858.Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:Ed000142. https:\/\/doi.org\/10.1002\/14651858.Ed000142.","journal-title":"Cochrane Database Syst Rev"},{"key":"5078_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/sjg.sjg_7_24","volume":"31","author":"A Alhadab","year":"2024","unstructured":"Alhadab A, et al. Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study. Saudi J Gastroenterol. 2024;31:59\u201367. https:\/\/doi.org\/10.4103\/sjg.sjg_7_24.","journal-title":"Saudi J Gastroenterol"},{"key":"5078_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jgh.16790","volume":"40","author":"Y Yamamoto","year":"2024","unstructured":"Yamamoto Y, et al. Long-term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn\u2019s disease with anti-tumor necrosis factor failure. J Gastroenterol Hepatol. 2024;40:123\u201332. https:\/\/doi.org\/10.1111\/jgh.16790.","journal-title":"J Gastroenterol Hepatol"},{"key":"5078_CR18","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1007\/s00431-024-05588-2","volume":"183","author":"G Pujol-Muncunill","year":"2024","unstructured":"Pujol-Muncunill G, et al. STEP-CD study: ustekinumab use in paediatric Crohn\u2019s disease-a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN. Eur J Pediatr. 2024;183:3253\u201362. https:\/\/doi.org\/10.1007\/s00431-024-05588-2.","journal-title":"Eur J Pediatr"},{"key":"5078_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5217\/ir.2019.09164","volume":"19","author":"A Cohen","year":"2021","unstructured":"Cohen A, Ahmed N, Sant\u2019Anna A. Ustekinumab for the treatment of refractory pediatric Crohn\u2019s disease: a single-center experience. Intest Res. 2021;19:217\u201324. https:\/\/doi.org\/10.5217\/ir.2019.09164.","journal-title":"Intest Res"},{"key":"5078_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/mpg.0000000000003230","volume":"73","author":"FS Kim","year":"2021","unstructured":"Kim FS, et al. Experience using ustekinumab in pediatric patients with medically refractory crohn disease. J Pediatr Gastroenterol Nutr. 2021;73:610\u20134. https:\/\/doi.org\/10.1097\/mpg.0000000000003230.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5078_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/jgh.15128","volume":"36","author":"I Takeuchi","year":"2021","unstructured":"Takeuchi I, et al. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children\u2019s hospital in Japan. J Gastroenterol Hepatol. 2021;36:125\u201330. https:\/\/doi.org\/10.1111\/jgh.15128.","journal-title":"J Gastroenterol Hepatol"},{"key":"5078_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/mpg.0000000000002362","volume":"69","author":"JR Dayan","year":"2019","unstructured":"Dayan JR, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69:61\u20137. https:\/\/doi.org\/10.1097\/mpg.0000000000002362.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5078_CR23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/mpg.0000000000003758","volume":"76","author":"M Koudsi","year":"2023","unstructured":"Koudsi M, et al. Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the pediatric GETAID. J Pediatr Gastroenterol Nutr. 2023;76:763\u201370. https:\/\/doi.org\/10.1097\/mpg.0000000000003758.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5078_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40272-024-00631-z","volume":"26","author":"S Cohen","year":"2024","unstructured":"Cohen S, et al. Effectiveness and Safety of Ustekinumab in pediatric ulcerative colitis: a multi-center retrospective study from the pediatric IBD Porto Group of ESPGHAN. Paediatr Drugs. 2024;26:609\u201317. https:\/\/doi.org\/10.1007\/s40272-024-00631-z.","journal-title":"Paediatr Drugs"},{"key":"5078_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.12688\/f1000research.22673.2","volume":"9","author":"P Do","year":"2020","unstructured":"Do P, et al. Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn\u2019s disease: a retrospective chart review. F1000Res. 2020;9:316. https:\/\/doi.org\/10.12688\/f1000research.22673.2.","journal-title":"F1000Res"},{"key":"5078_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.5217\/ir.2023.00091","volume":"22","author":"R Rehman","year":"2024","unstructured":"Rehman R, et al. Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing. Intest Res. 2024;22:351\u20136. https:\/\/doi.org\/10.5217\/ir.2023.00091.","journal-title":"Intest Res"},{"key":"5078_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/ecco-jcc\/jjy206","volume":"13","author":"M Chavannes","year":"2019","unstructured":"Chavannes M, et al. Management of paediatric patients with medically refractory crohn\u2019s disease using Ustekinumab: a multi-centred cohort study. J Crohns Colitis. 2019;13:578\u201384. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy206.","journal-title":"J Crohns Colitis"},{"key":"5078_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/mpg.0000000000003608","volume":"75","author":"A Yerushalmy-Feler","year":"2022","unstructured":"Yerushalmy-Feler A, et al. Safety and potential efficacy of escalating dose of Ustekinumab in pediatric crohn disease (the Speed-up Study): a multicenter study from the pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75:717\u201323. https:\/\/doi.org\/10.1097\/mpg.0000000000003608.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5078_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/jpn3.12384","volume":"80","author":"S R\u00e9bus","year":"2024","unstructured":"R\u00e9bus S, et al. Efficacy of vedolizumab and ustekinumab in pediatric-onset inflammatory bowel disease: a real-world multicenter study. J Pediatr Gastroenterol Nutr. 2024;80:113\u201323. https:\/\/doi.org\/10.1002\/jpn3.12384.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5078_CR30","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/ibd\/izae078","volume":"30","author":"I Iwama","year":"2024","unstructured":"Iwama I, et al. Ustekinumab offers long-term clinical remission with safety in very early-onset inflammatory bowel disease. Inflamm Bowel Dis. 2024;30:1220\u20132. https:\/\/doi.org\/10.1093\/ibd\/izae078.","journal-title":"Inflamm Bowel Dis"},{"key":"5078_CR31","doi-asserted-by":"publisher","first-page":"1371322","DOI":"10.3389\/fped.2024.1371322","volume":"12","author":"P Li","year":"2024","unstructured":"Li P, et al. Ustekinumab in pediatric patients with Crohn\u2019s disease: safety, and efficacy results from a multicenter retrospective study in China. Front Pediatr. 2024;12:1371322. https:\/\/doi.org\/10.3389\/fped.2024.1371322.","journal-title":"Front Pediatr"},{"key":"5078_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.crohns.2011.07.011","volume":"6","author":"MB Sprakes","year":"2012","unstructured":"Sprakes MB, et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn\u2019s disease: a large single centre experience. J Crohns Colitis. 2012;6:143\u201353. https:\/\/doi.org\/10.1016\/j.crohns.2011.07.011.","journal-title":"J Crohns Colitis"},{"key":"5078_CR33","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/ecco-jcc\/jjac006","volume":"16","author":"F Magro","year":"2022","unstructured":"Magro F, et al. ECCO position on harmonisation of crohn\u2019s disease mucosal histopathology. J Crohns Colitis. 2022;16:876\u201383. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac006.","journal-title":"J Crohns Colitis"},{"key":"5078_CR34","doi-asserted-by":"publisher","first-page":"i55","DOI":"10.1093\/ecco-jcc\/jjac190.0039","volume":"17","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, et al. OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC. J Crohns Colitis. 2023;17:i55\u20136. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0039.","journal-title":"J Crohns Colitis"},{"key":"5078_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3390\/biomedicines12051119","volume":"12","author":"M Omori","year":"2024","unstructured":"Omori M, et al. Remission factors for Ustekinumab treatment of ulcerative colitis: a multicenter retrospective study of real-world data in Japan. Biomedicines. 2024;12:1119. https:\/\/doi.org\/10.3390\/biomedicines12051119.","journal-title":"Biomedicines"},{"key":"5078_CR36","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.2174\/1381612043383638","volume":"10","author":"E Pfitzner","year":"2004","unstructured":"Pfitzner E, et al. The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des. 2004;10:2839\u201350. https:\/\/doi.org\/10.2174\/1381612043383638.","journal-title":"Curr Pharm Des"},{"key":"5078_CR37","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41597-024-03592-7","volume":"11","author":"C Martin-King","year":"2024","unstructured":"Martin-King C, et al. Histopathology imaging and clinical data including remission status in pediatric inflammatory bowel disease. Sci Data. 2024;11:761. https:\/\/doi.org\/10.1038\/s41597-024-03592-7.","journal-title":"Sci Data"},{"key":"5078_CR38","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1586\/17474124.2016.1174064","volume":"10","author":"G Pineton de Chambrun","year":"2016","unstructured":"Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2016;10:915\u201327. https:\/\/doi.org\/10.1586\/17474124.2016.1174064.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"5078_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/ecco-jcc\/jjac108","volume":"17","author":"D Casas-Deza","year":"2023","unstructured":"Casas-Deza D, et al. Effectiveness and safety of Ustekinumab in elderly patients with Crohn\u2019s disease: real world evidence from the ENEIDA registry. J Crohns Colitis. 2023;17:83\u201391. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac108.","journal-title":"J Crohns Colitis"},{"key":"5078_CR40","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/apt.17386","volume":"57","author":"C Taxonera","year":"2023","unstructured":"Taxonera C, et al. Meta-analysis: real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023;57:610\u20139. https:\/\/doi.org\/10.1111\/apt.17386.","journal-title":"Aliment Pharmacol Ther"},{"key":"5078_CR41","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. https:\/\/doi.org\/10.1136\/bmj.d4002.","journal-title":"BMJ"},{"key":"5078_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.12.040","author":"Z Huang","year":"2025","unstructured":"Huang Z, et al. Comparative effectiveness of infliximab vs ustekinumab for endoscopic and transmural remission in biologic Na\u00efve Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2024.12.040.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5078_CR43","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1053\/j.gastro.2020.08.037","volume":"159","author":"K Li","year":"2020","unstructured":"Li K, et al. Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis. Gastroenterology. 2020;159:2052\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.037.","journal-title":"Gastroenterology"},{"key":"5078_CR44","doi-asserted-by":"publisher","first-page":"1322054","DOI":"10.3389\/fimmu.2024.1322054","volume":"15","author":"W Zhang","year":"2024","unstructured":"Zhang W, et al. Research progress of Ustekinumab in the treatment of inflammatory bowel disease. Front Immunol. 2024;15:1322054. https:\/\/doi.org\/10.3389\/fimmu.2024.1322054.","journal-title":"Front Immunol"},{"key":"5078_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/ueg2.12275","volume":"10","author":"J Thunberg","year":"2022","unstructured":"Thunberg J, et al. Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register. United Eur Gastroenterol J. 2022;10:631\u20139. https:\/\/doi.org\/10.1002\/ueg2.12275.","journal-title":"United Eur Gastroenterol J"},{"key":"5078_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.dld.2021.07.008","volume":"54","author":"L Gonczi","year":"2022","unstructured":"Gonczi L, et al. Clinical efficacy, drug sustainability and serum drug levels in Crohn\u2019s disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary. Dig Liver Dis. 2022;54:207\u201313. https:\/\/doi.org\/10.1016\/j.dld.2021.07.008.","journal-title":"Dig Liver Dis"},{"key":"5078_CR47","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/ibd\/izae171","volume":"31","author":"CK Lee","year":"2025","unstructured":"Lee CK, et al. One-year safety and effectiveness of Ustekinumab in patients with Crohn\u2019s disease: the K-STAR study. Inflamm Bowel Dis. 2025;31:1306\u201316. https:\/\/doi.org\/10.1093\/ibd\/izae171.","journal-title":"Inflamm Bowel Dis"},{"key":"5078_CR48","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s10620-021-06932-4","volume":"67","author":"S Honap","year":"2022","unstructured":"Honap S, et al. Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis. Dig Dis Sci. 2022;67:1018\u201335. https:\/\/doi.org\/10.1007\/s10620-021-06932-4.","journal-title":"Dig Dis Sci"},{"key":"5078_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41575-023-00889-7","volume":"21","author":"S Danese","year":"2024","unstructured":"Danese S, Peyrin-Biroulet L. Are all the IL-23 blockers the same in inflammatory bowel disease? Nat Rev Gastroenterol Hepatol. 2024;21:138\u20139. https:\/\/doi.org\/10.1038\/s41575-023-00889-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5078_CR50","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/jpn3.70158","volume":"81","author":"LM Felipez","year":"2025","unstructured":"Felipez LM, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2025;81:1100\u201317. https:\/\/doi.org\/10.1002\/jpn3.70158.","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05078-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:02:46Z","timestamp":1792076566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05078-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5078"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05078-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. All patient data used in this study were sourced from previously published studies; therefore, no ethical approval was required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"652"}}